Enzyme kinetic properties of human recombinant arylamine n-acetyltransferase 2 allotypic variants expressed in Escherichia coli

Biochemical Pharmacology

Volumn 50, Issue 5, 1995, Pages 697-703

  Hickman, Dean ^a   Palamanda, Jairam R ^b   Unadkat, Jashvant D ^b   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acetyltransferase; arylamine; enzyme kinetics; human; pharmacogenetics; recombinant

Indexed keywords

2 FLUORENYLAMINE; ACYLTRANSFERASE; ANISIDINE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; DAPSONE; ISONIAZID; PROCAINAMIDE; RECOMBINANT ENZYME; SULFADIMIDINE; UNCLASSIFIED DRUG;

ACETYLATION; ALLELE; ALLOTYPE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME KINETICS; ENZYME STRUCTURE; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CLONING, MOLECULAR; DNA; ESCHERICHIA COLI; GENETIC VECTORS; HUMAN; ISOENZYMES; KINETICS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029143503     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)00182-Y     Document Type: Article

References (31)

1. Structural heterogeneity of Caucasian N-acetyltransferase at the NATI gene locus
2. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
3. Correlation between acetylator phenotype and genotypes of polymorphic arylamine N-acetyltransferase in human liver
4. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants
5. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slowacetylator allele common in African-Americans
6. Diverse point mutations in the human gene for polymorphic N-acetyltransferase
7. N-Acetyltransferase polymorphism: Comparison of phenotype and genotype in humans
8. N-Acetyltransferase
9. Slow N-Acetyltransferase genotype is a susceptibility factor in occupational and smoking related bladder cancer
10. Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiological evidence
11. The pharmacogenetics of chemical carcinogens
12. Genetically based N-acetyltransferase metabolic polymorphisms and low level exposure to carcinogens
13. Chromosomal localization of human genes for arylamine N-acetyltransferase.
14. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus
15. DNA sequencing with chain-terminating inhibitors
16. Use of T7 RNA polymerase to direct expression of cloned genes
17. New spectrophotometric and radiochemical assays for acetyl-CoA: Arylamine N-acetyltransferase applicable to a variety of arylamines
18. Determination of hydralazine and its metabolites by gas chromatography-mass spectrometry
19. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
20. Dapsone acetylation by human liver arylamine N-acetyltransferase and interaction with antiopportunistic infection drugs
21. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters
22. Monomorphic and polymorphic human arylamine N-acetyltransferase: A comparison of liver isozymes and expressed products of two cloned genes
23. Nomenclature for N-acetyltransferase
24. Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes
25. Acetylation phenotype and genotype in arboriginal leprosy patients from the north-west region of Western Australia
26. Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Columbia: High frequencies of point mutation 857A, as found in allele S3/M3
27. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene
28. Influence of chronic obstructive lung disease on the disposition of an acidic drug (sulfamethazine)
29. The polymorphic acetylation of dapsone in man
30. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver